Organization | University of Bristol

University of Bristol Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Bristol United Kingdom (1595)

Organization Overview

First Clinical Trial

1989

NCT00276718

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Bristol Children's Vaccine Centre | Bristol Haeamatology and Oncology Centre | Bristol Haematology & Oncology Centre | Bristol Haematology & Oncology Centre, Bristol | Bristol Heart Institute at University of Bristol | Bristol Myers Squibb Srl Italia | Bristol Royal Hospital for Children | Bristol Royal Infirmary | Bristol University, UK | Bristol Urological Institute | Hospital of Bristols, UK | Institute of Child Health at University of Bristol | North Bristol NHS Trust | North Bristol NHS Trust/University of Bristol | Univeristy of Bristol | University Hospitals Bristol NHS Foundation Trust | University Hospitals Bristol NHS Trust | University of Bristol

Active Ingredients

Drugs in Phase 4 Trials (29)

acamprosate (campral) (1 trial)

acetaminophen (tylenol) (3 trials)

carbamazepine (tegretol) (1 trial)

cephalexin (keflex) (1 trial)

citalopram (celexa) (1 trial)

clindamycin (cleocin) (1 trial)

clobazam (onfi) (1 trial)

clonazepam (klonopin) (1 trial)

codeine (Phenergan) (1 trial)

dextropropoxyphene (1 trial)

ethosuximide (zarontin) (1 trial)

flucloxacillin (1 trial)

isoflurane (forane) (1 trial)

lacosamide (vimpat) (1 trial)

lamotrigine (lamictal) (1 trial)

levetiracetam (keppra) (1 trial)

morphine (1 trial)

nitrazepam (1 trial)

nitrofurantoin (furadantin) (1 trial)

oxycodone (oxycontin) (1 trial)

phenytoin (mesantoin) (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

propofol (diprivan) (1 trial)

sitagliptin (januvia) (1 trial)

sofosbuvir (sovaldi) (1 trial)

tenofovir (viread) (1 trial)

trimethoprim (1 trial)

urea (2 trials)

velpatasvir (Epclusa) (1 trial)

Drugs in Phase 3 Trials (32)

anakinra (kineret) (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

carbetocin (1 trial)

carboplatin (paraplatin) (5 trials)

clonidine (catapres) (1 trial)

cyclophosphamide (cytoxan) (3 trials)

dactinomycin (cosmegen) (3 trials)

epirubicin (ellence) (3 trials)

ergonovine (1 trial)

etoposide (vepesid) (4 trials)

ifosfamide (ifex) (3 trials)

immune globulin (human) (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus delbrueckii (1 trial)

lactobacillus plantarum (1 trial)

l-epigallocatechin (1 trial)

mesalamine (rowasa) (1 trial)

methylprednisolone (medrol) (1 trial)

mycophenolate (myfortic) (1 trial)

nivolumab (opdivo) (1 trial)

oxytocin (syntocinon) (1 trial)

prednisone (meticorten) (2 trials)

prolycopene (1 trial)

rivastigmine (exelon) (1 trial)

sodium chloride (1 trial)

streptococcus salivarius (1 trial)

tomato (1 trial)

vincristine (oncovin) (3 trials)

vsl #3 (1 trial)

Drugs in Phase 2 Trials (22)

alemtuzumab (campath) (1 trial)

cabazitaxel (jevtana kit) (3 trials)

cisplatin (platinol) (2 trials)

diclofenac (voltaren) (2 trials)

doxorubicin (Doxil) (1 trial)

fludarabine (fludara) (1 trial)

inactivated influenza vaccine (2 trials)

insulin human (humulin) (1 trial)

lat8881 (1 trial)

melphalan (alkeran) (1 trial)

mesna (mesnex) (1 trial)

mirabegron (myrbetriq) (1 trial)

paclitaxel (taxol) (1 trial)

peripheral blood hematopoietic cell (1 trial)

sargramostim (leukine) (1 trial)

sativex (2 trials)

solifenacin (vesicare) (1 trial)

temozolomide (temodar) (1 trial)

xenon xe-133 (2 trials)

Drugs in Other Trials (4)

bleomycin (blenoxane) (1 trial)

levobupivacaine (chirocaine) (1 trial)

nicotine (nicorette) (1 trial)

varenicline (chantix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alcoholism (Phase 4)

Brain Diseases (Phase 2)

Brain Injuries (Phase 2)

Brain Ischemia (Phase 2)

Breast Neoplasms (Phase 2)

Cancer Pain (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Cellulitis (Phase 4)

Central Nervous System Neoplasms (Phase 2)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 4)

Diarrhea (Phase 3)

Epilepsy (Phase 4)

Femoral Fractures (Phase 4)

Femoral Neck Fractures (Phase 4)

Fractures, Bone (Phase 4)

Giant Cell Arteritis (Phase 3)

Glioblastoma (Phase 2)

Hemorrhage (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Histiocytoma (Phase 3)

Histiocytoma, Benign Fibrous (Phase 3)

Histiocytoma, Malignant Fibrous (Phase 3)

Hypertension (Phase 4)

Hypertension, Pulmonary (Phase 4)

Hypoxia-Ischemia, Brain (Phase 2)

Influenza, Human (Phase 2)

Intestinal Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lung Neoplasms (Phase 3)

Meningococcal Infections (Phase 2)

Myelitis (Phase 3)

Myelitis, Transverse (Phase 3)

Nervous System Neoplasms (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Neuromyelitis Optica (Phase 3)

Opioid-Related Disorders (Phase 4)

Osteoarthritis (Phase 2)

Parkinson Disease (Phase 3)

Penile Neoplasms (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Pneumococcal Infections (Phase 4)

Polymyalgia Rheumatica (Phase 3)

Postpartum Hemorrhage (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prediabetic State (Phase 4)

Prostatic Neoplasms (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Rhabdomyosarcoma (Phase 3)

Sarcoma (Phase 3)

Schizophrenia (Phase 4)

Sepsis (Phase 2)

Signs and Symptoms (Phase 2)

Thrombocytopenia (Phase 3)

Toxemia (Phase 2)

Ulcer (Phase 3)

Urinary Bladder Diseases (Phase 2)

Urinary Bladder, Overactive (Phase 2)

Urinary Tract Infections (Phase 4)

Urological Manifestations (Phase 2)

Urologic Diseases (Phase 2)

Uveitis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 48
# of Trial APIs: 87